Identification of serum markers mediating resistance to sunitinib in patients with renal cell carcinoma
Not Applicable
- Conditions
- renal cell carcinoma
- Registration Number
- JPRN-UMIN000004374
- Lead Sponsor
- Kobe University Graduate school of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Prior use of sunitinib Seizure disorder, evidence of brain metastases, spinal cord compression or carcinomatous meningitis. Active bacterial, fungal or viral infection. History of malignancy other than RCC except for those treated with curative intent with no evidence of disease for at least 2 years. Other severe acute or chronic medical condition.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Before and during treatment with sunitinib, measure serum levels of several molecules (E-cadherin, N-cadherin, fibronectin, MMP-2, MMP-3, MMP-9, MT-MMP-1, TIMP-1, TIMP-2, clusterin, bFGF, uPA and uPAR), which have been shown to be regulated by activated p44/42 MAPK and Akt and to be involved in the acquisition of an EMT phenotype in our preliminary experiments, in patients with metastatic RCC by sandwich enzyme-linked immunosorbent assay (ELISA) kits.
- Secondary Outcome Measures
Name Time Method